A compound (I) of the present invention, which has an EP1 receptor antagonism:[wherein A represents a benzene ring or the like Y1 represents a C1-6 alkylene group Y2represents a single bond or the like R1 represents a hydrogen atom, a C1-6 alkyl group or the like R2represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like R3represents a halogen atom, a C1-6 alkoxy group or the like R4 represents a hydrogen atom or the like and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
